Pyrazinoisoquinoline Derivatives for Selective TAAR1 Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medicaments targeting psychiatric and neurological disorders often exhibit undesirable side effects due to non-selectivity for Trace Amine Associated Receptors (TAARs) over adrenergic receptors, leading to suboptimal treatment outcomes.
Innovation Solution
Development of novel compounds of formula I, which demonstrate selectivity for TAAR1 receptors over adrenergic receptors, potentially offering improved therapeutic efficacy with reduced side effects for conditions such as depression, anxiety, ADHD, and Parkinson's disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds are designed to target adrenergic receptors for treating psychiatric and neurological disorders, then therapeutic effects may be achieved, but undesirable side effects occur due to non-selectivity over TAAR receptors
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular characteristics that enable selective interaction with TAAR1 receptors. The compounds of formula I feature particular substituent patterns (R1-R6 groups) and structural elements (pyrazino[2,2-a]isoquinoline core) that create localized binding affinity for TAAR1 while avoiding adrenergic receptor binding sites, thus achieving targeted therapeutic effects without off-target side effects.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters of the compounds including substituent types (halogen, alkyl, aryl groups), positions of substitution on the pyrazinoisoquinoline core, and stereochemical configurations. These parameter modifications tune the compounds' selectivity profile to preferentially bind TAAR1 over adrenergic receptors, resolving the contradiction between efficacy and side effects.
2Adaptability or versatility
If non-selective compounds are used to treat psychiatric and neurological disorders, then broader receptor coverage is achieved, but selectivity for TAAR1 over adrenergic receptors is lost
Solution Approach 1:
The patent applies segmentation by dividing the receptor target space into distinct segments: TAAR1 receptors and adrenergic receptors. The compounds of formula I are designed with specific structural segments (the pyrazinoisoquinoline pharmacophore with particular substituent patterns) that selectively engage the TAAR1 segment while deliberately avoiding the adrenergic receptor segment, achieving precise receptor selectivity rather than broad non-specific coverage.
3Object-affected harmful factors
If compounds with high TAAR1 selectivity are developed, then side effects are reduced, but therapeutic efficacy may be compromised
Solution Approach 1:
The patent uses the pyrazino[2,2-a]isoquinoline core structure as an intermediary pharmacophore that mediates selective binding to TAAR1 receptors. This core structure acts as a molecular bridge that specifically interfaces with TAAR1's binding pocket through its unique spatial arrangement and electronic properties, ensuring both high selectivity (reducing adverse effects) and sufficient affinity (maintaining therapeutic efficacy) simultaneously.
Data Source
AI summary
The present invention relates to compounds of formula of formula I wherein R, R1, R2 and L are as described herein, compositions containing compounds of formula I, methods of manufacture of compounds of formula I and methods of treating psychiatric, metabolic, cardiovascular or sleep disorders with compounds of formula I.